This application relates to methods for assessing patient populations and determining subpopulations vulnerable to viral infection, methods of reducing the risk of infection and/or inducing heterologous immunity to said viral infection.

This application relates to methods for assessing patient populations and determining subpopulations vulnerable to viral infection, methods of reducing the risk of infection and/or inducing heterologous immunity to said viral infection.

Disclosed herein are methods of selecting an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer. Also disclosed are methods of selecting a donor from whom to derive an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer.

Disclosed herein are methods of selecting an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer. Also disclosed are methods of selecting a donor from whom to derive an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer.

Provided are an ORF7 deficient varicella virus, an vaccine comprising the virus and use thereof, as well as a method for the production the virus.

Provided are an ORF7 deficient varicella virus, an vaccine comprising the virus and use thereof, as well as a method for the production the virus.

The present invention is directed to provide a modified CMV gB protein that can induce a group of antibodies including a high ratio of neutralizing antibodies that exhibit a high neutralizing activity against a CMV gB protein, in comparison with a wild type CMV gB, upon induction of immunity and that can be used in the prevention and/or treatment of CMV infection and a CMV vaccine comprising the modified CMV gB protein. The modified CMV gB protein according to the present invention is a modified CMV gB protein having an improved ability to induce body region-recognizing antibodies and comprising modification in a head region.

The present invention is directed to provide a modified CMV gB protein that can induce a group of antibodies including a high ratio of neutralizing antibodies that exhibit a high neutralizing activity against a CMV gB protein, in comparison with a wild type CMV gB, upon induction of immunity and that can be used in the prevention and/or treatment of CMV infection and a CMV vaccine comprising the modified CMV gB protein. The modified CMV gB protein according to the present invention is a modified CMV gB protein having an improved ability to induce body region-recognizing antibodies and comprising modification in a head region.

The invention relates to a viral vector comprising nucleic acid having a polynucleotide sequence encoding at least one epitope of the varicella-zoster virus (VZV) Gly E antigen, wherein said viral vector is an adenoviral vector. The invention also relates to uses, compositions for use in medical treatments, and methods of medical treatment.

The invention relates to a viral vector comprising nucleic acid having a polynucleotide sequence encoding at least one epitope of the varicella-zoster virus (VZV) Gly E antigen, wherein said viral vector is an adenoviral vector. The invention also relates to uses, compositions for use in medical treatments, and methods of medical treatment.